Larvol Delta - The-Company-also-anticipates-reading-out-data-from-a-Phase-1b-study-of-OST504-in-castration-resistant-prostate-cancer-in-the-first-half-of-2026

OST-504 - OS Therapies

https://markets.financialcontent.com/stocks/article/newsfile-2026-4-30-os-therapies-announces-ema-initiates-rolling-review-of-conditional-marketing-authorization-application-for-ost-her2-in-the-prevention-or-delay-of-recurrence-in-fully-resected-pulmonary-metastatic-osteosarcoma

Apr 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next